Life Molecular Imaging (LMI) is a global, innovative R&D company focusing on the development and commercialization of molecular imaging radiopharmaceuticals for our approved F-18 amyloid PET tracer Neuraceq® and a pipeline of PET tracers in clinical development. Our vision is to create value for patients and physicians by improving early detection and characterization of chronic and life-threatening diseases leading to better therapeutic outcomes and improved quality of life., At LMI, success stems from adaptability, resilience, and a commitment to our mission. We seek individuals who thrive in a dynamic, rapidly evolving environment and embrace the challenges and opportunities that come with growth. Our ideal candidates are proactive, solution-focused professionals who share our passion for advancing neuroimaging technology to transform the lives of patients affected by Alzheimer's and other neurodegenerative diseases.
What you can expect: A rewarding and challenging career with the support of their coworkers, managers, and other divisions of a global company. You will be able to make significant contributions through your expertise. You can expect what YOU do to matter, as all our employees are an integral part of a global organization as well as the communities we serve. The salary range for this position is $115 - 12k plus commission, along with a competitive benefits package including medical, dental, vision, life & disability, 401k, and PTO.
Life Molecular Imaging, Inc. is an Equal Opportunity Employer. We believe what we do and our culture of "More Than a Job. It's Making Life Better" extends to creating a welcoming, safe, and inclusive work environment. If you have what it takes and the passion to make a difference, please apply
Ihre Aufgaben
Responsible for business development and execution of strategies to effectively capitalize on sales opportunities in collaboration with Life Molecular Imaging's goals and objectives. This individual will work in the specialized market of Neuro-Molecular Imaging within large specialty practices, specialty imaging facilities, and further expanding opportunities. The responsibilities below do not represent the entirety of the role but rather an overview of some of the key tasks. Key Tasks and Responsibilities:
-
Develop strong relationships with healthcare providers and their staff members to earn their trust, business, and referrals.
-
Collaborate with RSM to design and execute a strategy to capitalize and close on sales opportunities.
-
Analyze and understand competitive market conditions and the changing needs of customers; modify strategy as needed.
-
Promote internal value-add services that enhance the relationship and differentiate LMI as the partnership of choice.
-
Direct sales experience in radiopharmaceuticals, molecular imaging, neurology. Similar fields will be considered.
-
Knowledge of PET, nuclear radiopharmaceuticals, and molecular imaging.
-
Established record of building physician, referrer, and imaging center relationships.
-
Ability to travel extensively in territory., Errors may occur in the Neuraceq estimation of brain neuritic β-amyloid plaque density during image interpretation [see Clinical Studies (14)]. Image interpretation should be performed independently of the patient's clinical information. The use of clinical information in the interpretation of Neuraceq images has not been evaluated and may lead to errors. Errors may also occur in cases with severe brain atrophy that limits the ability to distinguish gray and white matter on the Neuraceq scan. Errors may also occur due to motion artifacts that result in image distortion. Neuraceq scan results are indicative of the presence of brain neuritic β-amyloid plaques only at the time of image acquisition and a negative scan result does not preclude the development of brain neuritic β-amyloid plaques in the future.
-
Radiation Risk Neuraceq, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [see Dosage and Administration.
ADVERSE REACTIONS:
-
The most commonly reported adverse reactions in clinical trials were injection site pain (3.4%), injection/appliucation site erythema (1.7%), injection site irritation (1.1%).
DRUG INTERACTIONS
-
Drug-drug interaction studies have not been performed in patients to establish the extent, if any, to which concomitant medications may alter Neuraceq image results.
Kontakt
SUSPECTED ADVERSE REACTIONS please report to: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program